Paxlovid Kit
NDC Package 0069-0521-11

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is approaching its end of marketing date. An upcoming end of marketing date means the product has been delisted but will remain in the NDC database until the end of marketing date is reached. In most cases, the FDA advises firms to use the expiration date of the last lot produced as the end marketing date, reflecting the possibility that the product may still be available even after manufacturing has stopped.

Paxlovid (nirmatrelvir and ritonavir) kits is pAXLOVID is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults who are at high risk for progression to severe COVID-19, including hospitalization or death. This formulation utilizes a kit delivery system. Marketed by Pfizer Laboratories Div Pfizer Inc, this product is identified by NDC 0069-0521 and is authorized under FDA application NDA217188.

Identification & Billing

NDC Package Code
0069-0521-11
Package Description
1 BLISTER PACK in 1 CARTON / 1 KIT in 1 BLISTER PACK * 6 TABLET, FILM COATED in 1 BLISTER PACK (0069-2085-06) * 5 TABLET, FILM COATED in 1 BLISTER PACK (0069-1735-05)
Product Code
0069-0521
11-Digit Billing Format
00069052111
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
RxNorm Crosswalk
  • RxCUI: 2587897 - nirmatrelvir 150 MG Oral Tablet
  • RxCUI: 2587898 - {20 (nirmatrelvir 150 MG Oral Tablet) / 10 (ritonavir 100 MG Oral Tablet) } Pack
  • RxCUI: 2587898 - nirmatrelvir 300 MG ; ritonavir 100 MG Daily Dose Pack
  • RxCUI: 2587898 - nirmatrelvir 150 MG Oral Tablet (20) / ritonavir 100 MG Oral Tablet (10) 5-Day Pack
  • RxCUI: 2587899 - {20 (nirmatrelvir 150 MG Oral Tablet) / 10 (ritonavir 100 MG Oral Tablet) } Pack [Paxlovid 5-Day]

Clinical Specifications

Proprietary Name
Paxlovid
Non-Proprietary Name
Nirmatrelvir And Ritonavir
Dosage Form
Kit - A packaged collection of related material.
Usage Information
PAXLOVID is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.

Regulatory & Marketing

Labeler Name
Pfizer Laboratories Div Pfizer Inc
Product Type
Human Prescription Drug
FDA Application #
NDA217188
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
04-15-2025
End Marketing Date
08-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0069-0521-11 identifies a specific commercial package of 1 blister pack in 1 carton / 1 kit in 1 blister pack * 6 tablet, film coated in 1 blister pack (0069-2085-06) * 5 tablet, film coated in 1 blister pack (0069-1735-05) of Paxlovid, a human prescription drug labeled by Pfizer Laboratories Div Pfizer Inc. This kit is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Pfizer Laboratories Div Pfizer Inc on April 15, 2025.

How is this Pfizer Laboratories Div Pfizer Inc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00069052111. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0069-0521-11
11-Digit CMS (5-4-2)
00069-0521-11

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.